Novartis Pharma AG

In May 2003, Idenix signed a license agreement with Novartis Pharma AG for the worldwide development and commercialization of certain drug candidates, including Tyzeka/Sebivo®. For more information about our collaboration with Novartis Pharma AG, please refer to our public filings with the Securities and Exchange Commission which can be accessed via our Investor Relations page.